Furthermore, in combination with DOX, RPDC-HI remarkably improves the tumor inhibition efficacy to 97.5% in treating HER2-positive breast cancer, compared to only 34.3% for free DOX [59]. Here, ERBB2 is linked to breast carcinoma.